Literature DB >> 11022911

Quantitative determination of pravastatin and its biotransformation products in human serum by turbo ion spray LC/MS/MS.

D Mulvana1, M Jemal, S C Pulver.   

Abstract

A sensitive, specific, accurate and reproducible analytical method was developed and validated to quantify pravastatin (Prav), pravastatin-d5 (Prav-d5), SQ-31906, SQ-31906-d5, and pravastatin lactone (Prav-Lac) in human serum samples. Serum samples (0.5 ml) were acidified and extracted by a solid-phase extraction procedure to isolate all five analytes from human serum. Sample extracts were reconstituted and analyzed by turbo ion spray liquid chromatography/tandem mass spectrometry (LC/MS/MS) in the positive ion mode. The total run time was 9 min between injections. The assay demonstrated a lower limit of quantitation (LLQ) of 0.5 ng/ml for all five analytes. The calibration curves were linear from 0.5 ng ml to 100 ng/ml for all five analytes. The coefficients of determination of all calibration curves were > or = 0.999. Precision and accuracy quality control (QC) samples were prepared at concentrations of 2, 30, 80, and 500 ng/ml for all analytes. The intra-assay and inter-assay precision calculated from QC samples were within 8%, for all analytes. The inter-assay accuracy calculated from QC samples was within 8% for all analytes. The extraction recoveries were > or = 90% for all analytes. Benchtop stability experiments in an ice-water bath ( < or = 10 degrees C) demonstrated that over time, Prav-Lac hydrolyzes to Prav in serum. Prav, Prav-d5, SQ-31906, and SQ-31906-d5 were stable under these conditions for up to 24 h. Hydrolysis was minimized by buffering the serum to pH 4.5 and maintaining the serum sample in an ice-water bath. All analytes were stable after three freeze/thaw cycles and in reconstitution solution after 1 week at 4 degrees C. Stability of all analytes in human serum was demonstrated after storage at -70 degrees C for 77 days. The benchtop (< or = 10 degrees C) stability of pooled study samples was also investigated and the results were comparable to those obtained from serum QC samples.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11022911     DOI: 10.1016/s0731-7085(00)00372-1

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  7 in total

1.  Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.

Authors:  Mia Hedman; Marjatta Antikainen; Christer Holmberg; Mikko Neuvonen; Michel Eichelbaum; Kari T Kivistö; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2006-06       Impact factor: 4.335

2.  No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin.

Authors:  Jenni E Keskitalo; Kaisa J Kurkinen; Mikko Neuvonen; Janne T Backman; Pertti J Neuvonen; Mikko Niemi
Journal:  Br J Clin Pharmacol       Date:  2009-08       Impact factor: 4.335

3.  Role of intestinal cytochrome P450 (P450) in modulating the bioavailability of oral lovastatin: insights from studies on the intestinal epithelium-specific P450 reductase knockout mouse.

Authors:  Yi Zhu; Jaime D'Agostino; Qing-Yu Zhang
Journal:  Drug Metab Dispos       Date:  2011-02-24       Impact factor: 3.922

4.  Liquid chromatography-tandem mass spectrometry assay for the simultaneous quantification of simvastatin, lovastatin, atorvastatin, and their major metabolites in human plasma.

Authors:  Jiang Wang; Jasmine A Luzum; Mitch A Phelps; Joseph P Kitzmiller
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2015-01-13       Impact factor: 3.205

5.  Quantitative determination of pravastatin and its metabolite 3α-hydroxy pravastatin in plasma and urine of pregnant patients by LC-MS/MS.

Authors:  Xing Zhang; Daria I Vernikovskaya; Xiaoming Wang; Tatiana N Nanovskaya; Maged Costantine; Gary D V Hankins; Mahmoud S Ahmed
Journal:  Biomed Chromatogr       Date:  2015-09-11       Impact factor: 1.902

6.  Effect of rifampicin on pravastatin pharmacokinetics in healthy subjects.

Authors:  Carl Kyrklund; Janne T Backman; Mikko Neuvonen; Pertti J Neuvonen
Journal:  Br J Clin Pharmacol       Date:  2004-02       Impact factor: 4.335

7.  Quantitative determination of pravastatin in pharmaceutical dosage forms by high-performance liquid chromatography with ultraviolet detection.

Authors:  Safwan Ashour; Husni Nakshbandi; Soulafa Omar
Journal:  Int J Biomed Sci       Date:  2008-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.